Top in hem/onc: Highlights from the San Antonio Breast Cancer Symposium

Data presented at the San Antonio Breast Cancer Symposium showed that aromatase inhibitors reduced the risk for breast cancer recurrence among certain premenopausal women compared with tamoxifen.

Researchers observed this benefit in women treated with ovarian suppression for ER-positive early-stage disease. It was the top story in hematology/oncology last week.

Another top story discussed how tumor biology was more important than race in predicting treatment outcomes for patients with high-risk breast cancer.

Read these and more top stories in hematology/oncology below:

Aromatase inhibitors benefit certain premenopausal women with early breast cancer

Aromatase inhibitors may reduce breast cancer recurrence compared with tamoxifen for certain premenopausal women with breast cancer, according to study results. Read more.

Tumor biology predicts breast cancer treatment outcomes more than race

Race did not significantly predict response to treatment outcomes among women with high-risk breast cancer, data showed. Read more.

Early treatment switch may benefit patients with estrogen receptor mutations

A liquid biopsy-based approach to treatment selection improved outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer, according to researchers. Read more.

Metformin does not improve outcomes in early breast cancer

Researchers reported that that metformin did not improve outcomes for most patients with early breast cancer. Read more.

Black women at greatest risk for breast cancer-related lymphedema

Black and Hispanic women appeared more likely than white women to develop breast cancer-related lymphedema, according to study results. Read more.